

Oracellular Dermis



Oracell eliminates the need for a palatal surgical site, reducing post-operative morbidity and surgical time — with no statistical difference in outcomes for treatment of gingival recessions defects compared to connective tissue graft (CTG).

PUBLICATION: The Open Dentistry Journal

TITLE: A Comparative Study of Root Coverage using Oracell Versus Subepithelial Connective Tissue: A Randomized Controlled Trial.

AUTHOR: Vreeburg SK, Griffiths GR, Rossmann JA

METHODS: Twenty-four non-smoking, healthy patients, with 2mm or greater facial gingival recession at a minimum of one site that is classified as Miller Class I, II, or III recession defects were included. All root coverage clinical parameters were evaluated at baseline, 3, and 6-months.

RESULTS: Eleven patients received CTG while 13 patients received Oracell; 23 of the 24 total patients had Miller Class III defects. Differences between group means were not statistically significant.

Both Oracell and CTG showed significant improvement in vertical and horizontal recession at both three and six months compared to baseline.

Probing depth for both Oracell and CTG remained relatively unchanged at six months.

Both CTG and Oracell had equal significant improvement, in clinical attachment level at three months and six months.

Oracell provides a viable alternative to CTG in Miller Class III recession defects.

Convenience

Oracell is preserved with Preservon®. This proprietary technology allows the decellularized dermis to be stored at room temperature and is ready to use out of the package. Using this patented technology, the need to thaw and rehydrate dermal allografts is eliminated, reducing allograft prep time to as little as 30 seconds and saving valuable operating room time without compromising product integrity.

Safety

Oracell is sterilized to a Sterility Assurance Level (SAL) of 10⁻⁶ rendering the tissue medical device-grade sterile without compromising the biomechanical or desired biochemical properties.

Processing Matters

Oracell undergoes proprietary Matracell® processing that has demonstrated less residual DNA and better tissue ingrowth than competitors in laboratory testing.





| Oracell Acellular Dermis | | | |
|--------------------------|-----------|------------|------------|
| Thickness (mm) | Size (mm) | Shelf Life | Order Code |
| 0.76 - 1.25 | 10 x 10 | 18 Months | OCELL 150 |
| | 10 x 40 | 3 Years | OCELL 151 |
| | 15 x 20 | 18 Months | OCELL 100 |
| | 20 x 40 | 18 Months | OCELL 101 |
| 1.26 - 1.75 | 10 x 10 | 18 Months | OCELL 250 |
| | 10 x 40 | 3 Years | OCELL 251 |
| | 15 x 20 | 18 Months | OCELL 200 |
| | 20 x 40 | 18 Months | OCELL 201 |

Since 1982, LifeNet Health has helped to save lives, restore health and give hope for thousands of patients each year. It is the world's most trusted provider of transplant solutions, from organ procurement to new innovations in bio-implant technologies and cellular therapies—a leader in the field of regenerative medicine, while always honoring the donors and healthcare professionals that allow the healing process.

At LifeNet Health, we deliver that value by excelling in four critical areas:



1864 Concert Drive Virginia Beach, VA 23453 1-888-847-7831 (US & Canada) 1-757-464-4761 ext. 2000 (OUS)

LifeNetHealth.org

The LifeNet Health logo, Matracell, Oracell, and Preservon are registered trademarks of LifeNet Health, Virginia Beach, VA.

©2019 LifeNet Health. All rights reserved.

68-20-235.00



